ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1928

Outcomes Of The Fast-Track Pathway In Giant Cell Arteritis: A Sight Saver

Pravin Patil1, Win Win Maw1, Katerina Achilleos1, Christian Dejaco2,3, Mark Williams4, Tochukwu Adizie2, Dimitrios Christidis5, Frances Borg1 and Bhaskar Dasgupta2, 1Rheumatology, Southend University Hospital, Westcliff-on-sea, United Kingdom, 2Rheumatology, Southend University Hospital, Westcliff-on-Sea, United Kingdom, 3Department of Rheumatology and Immunology, Medical University Graz, Graz A-8036, Austria, 4Rheumatology, Southend University Hospital, Westcliff on sea, United Kingdom, 5Rheumatology, Southend University Hospital, Westcliffe on sea, United Kingdom

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Giant cell arteritis and management

  • Tweet
  • Email
  • Print
Session Information

Title: Health Services Research, Quality Measures and Quality of Care - Innovations in Health Care Delivery

Session Type: Abstract Submissions (ACR)

Outcomes of the fast-track pathway in Giant cell arteritis: A sight saver

Background/Purpose:   Giant cell arteritis (GCA) is a medical emergency, with permanent visual loss occurring in about 20-30% of patients. We have identified that delayed recognition, multiplicity of referral routes and absence of a standard pathway of care increases the complications rate in GCA. We report our experience of developing and implementation of a fast-track referral pathway (FTP) to reduce the incidence of sight loss in GCA.

Methods: All patients with suspected GCA seen between Jan 2012 to Dec 2012 were enrolled into a FTP. Patients were started immediately on high dose glucocorticosteroids (GC) by the referring doctor and seen by a rheumatologist within one working day. We compared data from the FTP with that of a longitudinal cohort of suspected GCA patients seen through standard referral routes between January 2009 and December 2012. A logistic regression method was used to investigate the effect of several variables on sight loss.

Results:  GCA was diagnosed in 46 (56.8%) patients in the standard pathway and in 33 (58.9%) in the FTP. As shown in table 1, complete sight loss was more commonly observed in standard compared to FTP [n=17 (37.0%) versus 3 (9.1%), p=0.005 in univariate and p=0.007 in multivariate analysis adjusting for clinical risk factors of sight loss]. There was no difference in the staring dose of GC or the number of patients receiving intravenous GC in both groups.

In the standard pathway, a higher proportion of GCA patients were referred to other specialties before rheumatology [n=11 (23.9%) vs. n=5 (15.2%), p=0.34].  The majority of patients in FTP were seen within a day of presenting to general practitioner compared to a median time of 3.0 (1.0-71.0 days) in the standard pathway (p=0.068). Interestingly, a significantly lower number of patients who subsequently lost sight presented with headache [n=13 (65.0%)] compared to those who did not lose sight [57 (98.3), p<0.001].

Table 1. Types of sight loss in conventional and fast track pathways

Type of sight loss

GCA – conventional

(n=17)

GCA –fast track

(n=3)

Partial, monocular¥

6 (35.3)

1 (33.3)

Complete, monocular¥

8 (47.1)

2 (66.7)

Partial, binocular¥

0

0

Complete, binocular¥

3 (17.6)

0

¥ n (percentage)

Conclusion: Implementation of a GCA fast track pathway led to a reduction of permanent sight loss in newly referred GCA patients. The effect is explained by a reduction of the delay in treatment of GCA as well as by other, difficult to measure factors including increased awareness of GCA by public and general practitioners and reduction in the multiplicity of referral routes to rheumatology clinic. We recommend adoption of the FTP as a standard of care for GCA.


Disclosure:

P. Patil,
None;

W. W. Maw,
None;

K. Achilleos,
None;

C. Dejaco,
None;

M. Williams,
None;

T. Adizie,
None;

D. Christidis,
None;

F. Borg,
None;

B. Dasgupta,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/outcomes-of-the-fast-track-pathway-in-giant-cell-arteritis-a-sight-saver/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology